Repligen Corp (NASDAQ:RGEN) is set to release its Q4 2024 earnings on Feb 20, 2025. The consensus estimate for Q4 2024 ...

Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) met Wall Street’s revenue expectations in Q4 CY2024, but ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Repligen (RGEN – Research Report), Springworks ...

Repligen Corp (RGEN) reports robust fourth-quarter revenue growth, driven by product differentiation and strategic initiatives, while setting optimistic guidance for 2025.

Repligen (RGEN) came out with quarterly earnings of $0.44 per share, beating the Zacks Consensus Estimate of $0.41 per share. This compares to earnings of $0.33 per share a year ago. These figures are ...

Reports Q4 revenue $168M, consensus $167.57M. Olivier Loeillot, President and Chief Executive Officer of Repligen (RGEN) said, “During the ...

（全球 TMT2024 年 9 月 3 日讯）SAP SE 宣布，SAP 监事会已经与首席技术官兼执行董事会成员 Dr.-Ing. J ü rgen M ü ller 达成了一项共同协议。J ü rgen M ü ller ...

Repligen expects full-year earnings in the range of $1.67 to $1.76 per share, with revenue in the range of $685 million to $710 million. This story was generated by Automated Insights ( ...

Key Insights The projected fair value for Repligen is US$264 based on 2 Stage Free Cash Flow to Equity Repligen ...